Vanguard Capital Management’s Compass Therapeutics CMPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.23M Sell
5,994,782
-124,000
-2% -$256K ﹤0.01% 2999
2026
Q2
$13.4M Buy
6,118,782
+81,607
+1% +$241K ﹤0.01% 2662
2026
Q1
$31.9M Buy
+6,037,175
New +$34.8M ﹤0.01% 2088

Other funds holding CMPX

Vanguard Capital Management's CMPX Position: Q3 2026 in Review

Vanguard Capital Management reduced its Compass Therapeutics (CMPX) stake by 2% in Q3 2026, selling an estimated $256K and leaving 5,994,782 shares worth $6.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2999.

Vanguard Capital Management first reported a position in CMPX in Q1 2026 and has held it in 3 quarters since. The position peaked at $31.9M in Q1 2026. 172 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Vanguard Capital Management held 5,994,782 shares of Compass Therapeutics worth $6.23M as of Q3 2026.
  • Vanguard Capital Management sold 124,000 Compass Therapeutics shares in Q3 2026, an estimated $256K.
  • Compass Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2999 holding.
  • Vanguard Capital Management first reported a position in Compass Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Compass Therapeutics position peaked at $31.9M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.